Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

lung carcinoma
stage iv non-small cell lung cancer
EGFR
gefitinib
metastasis
  • 14 views
  • 25 Jan, 2021
  • 8 locations
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable

serum bilirubin level
solid tumour
kidney function test
stage iv non-small cell lung cancer
carboplatin
  • 107 views
  • 29 Jan, 2021
  • 41 locations
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation.

serum bilirubin level
measurable disease
lung carcinoma
tyrosine
epidermal growth factor
  • 0 views
  • 01 Feb, 2021
  • 1 location
  • 0 views
  • 26 Jan, 2021
  • 23 locations
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer Urothelial Cancer and Malignant Mesothelioma

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

lung cancer
lung carcinoma
cancer
cancer chemotherapy
pemetrexed
  • 0 views
  • 27 Jan, 2021
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective …

squamous non-small cell lung cancer
cancer
crizotinib
ROS1
measurable disease
  • 0 views
  • 11 Apr, 2021
  • 1 location
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over

serum bilirubin level
lung carcinoma
atezolizumab
recurrent non-small cell lung cancer
EGFR
  • 0 views
  • 09 Apr, 2021
  • 1 location
Testing the Addition of the Pill Chemotherapy Cabozantinib to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung

measurable disease
monoclonal antibodies
hepatitis c virus
chronic hepatitis b
pd-l1
  • 25 views
  • 11 May, 2021
  • 446 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

BRAF
pemetrexed
stage iv non-small cell lung cancer
EGFR
LKB1
  • 389 views
  • 07 Mar, 2021
  • 79 locations
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial (CX-839-014, otherwise known as the KEAPSAKE trial). Circulating tumor DNA (ctDNA) present in blood samples collected …

  • 0 views
  • 05 Mar, 2021
  • 60 locations